CEACAM5 and colorectal carcinoma: A recent investigation has shown that 30–50% of CRC patients encounter recurrence after successful treatment therapy, and currently the carcinoembryonic antigen (CEA) blood test is the gold standard to monitor its recurrence, which lacks sensitivity and specificity to precisely prognose the disease [57].